skip to main content

Lidocaine hepatic metabolism — FRCA Primary MCQ

Instant feedback + full explanation. One question, done properly.

HardPharmacologyLidocaine hepatic metabolismFRCA Primary

A patient with decompensated cirrhosis and low cardiac output receives a prolonged intravenous lidocaine infusion. Perioral paraesthesia and confusion develop despite a previously acceptable rate. Which paired pharmacokinetic change is most likely?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: BReduced hepatic clearance with prolonged active-metabolite exposure

The best answer is “Reduced hepatic clearance with prolonged active-metabolite exposure”. Lidocaine is an amide local anaesthetic whose clearance depends heavily on hepatic metabolism and hepatic blood flow. Liver disease and low cardiac output therefore prolong parent-drug exposure; active metabolites may also accumulate during extended infusions. Hofmann degradation and plasma-esterase hydrolysis apply to other drugs, while less than a small fraction of lidocaine is excreted unchanged.

Reference: Lidocaine 10 mg/mL solution for injection, UK SmPC: https://www.medicines.org.uk/emc/product/12562/smpc; Royal College of Anaesthetists, Primary FRCA syllabus v2.2: https://www.rcoa.ac.uk/sites/default/files/documents/2026-01/Primary-FRCA-Syllabus.pdf